Di Sciullo, M. P., Menay, F., Cocozza, F., Gravisaco, M. J., Waldner, C. I., & Mongini, C. (2019). Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma. Web
Citación estilo ChicagoDi Sciullo, Maria Paula, Florencia Menay, Federico Cocozza, María José Gravisaco, Claudia Ines Waldner, and Claudia Mongini. Systemic Administration of Imiquimod As an Adjuvant Improves Immunogenicity of a Tumor-lysate Vaccine Inducing the Rejection of a Highly Aggressive T-cell Lymphoma. 2019.
Cita MLADi Sciullo, Maria Paula, et al. Systemic Administration of Imiquimod As an Adjuvant Improves Immunogenicity of a Tumor-lysate Vaccine Inducing the Rejection of a Highly Aggressive T-cell Lymphoma. 2019.